Literature DB >> 15465508

Adult phenylketonuria.

W B Hanley1.   

Abstract

Newborn screening for phenylketonuria began 35 to 40 years ago in most industrialized countries. Because of this initiative, which resulted in early institution of phenylalanine-restricted diets, there are now many young adults with this disease who have normal or near-normal intellectual function. In North America alone, 200 patients with phenylketonuria enter adulthood every year. Most expert panels recommend following a phenylalanine-restricted "diet for life." However, there are few adult physicians dedicated to continuing care of this group, with the possible exception of maternal phenylketonuria. Up to 10% of adults with classic phenylketonuria, and possibly 50% of those with milder variants, may not need treatment; after adolescence, intelligence does not appear to deteriorate, at least into early adulthood, even if diet therapy is discontinued or not in good control. However, neuropsychological and psychosocial problems develop frequently, needing focused and intensive support by health care providers. New investigative methods and treatment options are on the horizon. There is an urgent need for physicians who will orchestrate the care of adults with phenylketonuria.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15465508     DOI: 10.1016/j.amjmed.2004.03.042

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  29 in total

1.  Tackling frontal lobe-related functions in PKU through functional brain imaging: a Stroop task in adult patients.

Authors:  Benedikt Sundermann; Bettina Pfleiderer; Harald E Möller; Wolfram Schwindt; Josef Weglage; Jöran Lepsien; Reinhold Feldmann
Journal:  J Inherit Metab Dis       Date:  2011-04-14       Impact factor: 4.982

Review 2.  Reversing neurodevelopmental disorders in adults.

Authors:  Dan Ehninger; Weidong Li; Kevin Fox; Michael P Stryker; Alcino J Silva
Journal:  Neuron       Date:  2008-12-26       Impact factor: 17.173

Review 3.  Antioxidant treatment strategies for hyperphenylalaninemia.

Authors:  Priscila Nicolao Mazzola; George Albert Karikas; Kleopatra H Schulpis; Carlos Severo Dutra-Filho
Journal:  Metab Brain Dis       Date:  2013-05-09       Impact factor: 3.584

4.  A novel compound-primed multiplex ARMS-PCR (CPMAP) for simultaneous detection of common PAH gene mutations.

Authors:  Maryam Shaykholeslam Esfahani; Ehsan Shaykholeslam Esfahani; Sadeq Vallian
Journal:  Metab Brain Dis       Date:  2018-04-03       Impact factor: 3.584

Review 5.  Emerging pharmacotherapies for neurodevelopmental disorders.

Authors:  Daniel Z Wetmore; Craig C Garner
Journal:  J Dev Behav Pediatr       Date:  2010-09       Impact factor: 2.225

6.  Management of adult patients with phenylketonuria: survey results from 24 countries.

Authors:  Friedrich K Trefz; Francjan J van Spronsen; Anita MacDonald; François Feillet; Ania C Muntau; Amaya Belanger-Quintana; Alberto Burlina; Mübeccel Demirkol; Marcello Giovannini; Christoph Gasteyger
Journal:  Eur J Pediatr       Date:  2014-12-06       Impact factor: 3.183

7.  Phenylketonuria: an inborn error of phenylalanine metabolism.

Authors:  Robin A Williams; Cyril D S Mamotte; John R Burnett
Journal:  Clin Biochem Rev       Date:  2008-02

8.  Maternal hyperphenylalaninemia: rapid achievement of metabolic control predicts overall control throughout pregnancy.

Authors:  Teresa Martino; Celide Koerner; Gayane Yenokyan; Julie Hoover-Fong; Ada Hamosh
Journal:  Mol Genet Metab       Date:  2013-02-19       Impact factor: 4.797

9.  Phenylalanine induces oxidative stress and decreases the viability of rat astrocytes: possible relevance for the pathophysiology of neurodegeneration in phenylketonuria.

Authors:  Thales Preissler; Ivi Juliana Bristot; Bruna May Lopes Costa; Elissa Kerli Fernandes; Elenara Rieger; Vanessa Trindade Bortoluzzi; Itiane Diehl de Franceschi; Carlos Severo Dutra-Filho; José Claudio Fonseca Moreira; Clovis Milton Duval Wannmacher
Journal:  Metab Brain Dis       Date:  2015-11-16       Impact factor: 3.584

10.  Adult reversal of cognitive phenotypes in neurodevelopmental disorders.

Authors:  Alcino J Silva; Dan Ehninger
Journal:  J Neurodev Disord       Date:  2009-06-17       Impact factor: 4.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.